Real Patients Talk About the Hand Condition
and Treatments
- Six short, unscripted "Coffee & Cords" videos explore
various topics, including the tabletop test, finding a hand
specialist and discussing treatment options
- Videos can be seen online, with digital and social
advertising to come later this year
DUBLIN, Oct. 5, 2022 /PRNewswire/ -- Endo International
plc (OTC: ENDPQ) announced today the launch of its new branded
video series, Coffee & Cords, which aims to
educate people about Dupuytren's contracture (DC), a progressive
hand condition that results in the formation of a collagen
rope-like cord that pulls fingers toward the palm and affects an
estimated 14 million Americans.
The Coffee & Cords videos feature five real patients
with DC in a coffee shop discussing their experiences with the
finger contracture condition, including the impact on their daily
activities and treatment options. The conversations are unscripted
and present the patients' actual experiences and views.
"Those who best understand and relate to DC patients are other
patients—they've faced similar physical challenges, feelings about
the condition and hesitations or confusion around treatment," said
Justin Mattice, Vice President &
General Manager, Medical Therapeutics at Endo. "We believe these
authentic voices can empower others who think they may have DC to
talk to a hand surgeon about treatment options, including
XIAFLEX® (collagenase clostridium histolyticum), the
only FDA-approved nonsurgical treatment for adults with DC with a
palpable cord."
Do not receive XIAFLEX if you have had an allergic
reaction to collagenase clostridium histolyticum or any of the
ingredients in XIAFLEX, or to any other collagenase product.
The six Coffee & Cords videos range from one to four
minutes in length. The short episodes focus on specific topics so
that people can easily find what they're interested in, or they can
watch the entire series to get a fuller view of the patient
experience—dealing with the effects of the finger contraction
condition, understanding DC, doing the tabletop test, finding a
hand specialist and discussing treatment options.
The videos are viewable on Endo's newly redesigned consumer
website for XIAFLEX, found at XIAFLEX.com. Later this year, they
will be used in digital and social advertising.
About Dupuytren's Contracture
DC is a lifelong
condition that may get worse over time. It's caused by a buildup of
collagen in the hand, which forms a rope-like cord that pulls
fingers toward the palm so they can't be straightened. As DC
progresses, it may become difficult for individuals to use their
hand(s) for daily tasks and activities.
WHAT IS XIAFLEX®?
XIAFLEX is a prescription medicine used to treat adults with
Dupuytren's contracture when a "cord" can be felt. It is not known
if XIAFLEX is safe and effective in children under the age of
18.
IMPORTANT SAFETY INFORMATION FOR XIAFLEX
Do not receive XIAFLEX if you have had an allergic
reaction to collagenase clostridium histolyticum or any of the
ingredients in XIAFLEX, or to any other collagenase product. See
the end of the Medication Guide for a complete list of ingredients
in XIAFLEX.
XIAFLEX can cause serious side effects, including:
- Tendon rupture or ligament damage. Receiving an
injection of XIAFLEX may cause damage to a tendon or ligament in
your hand and cause it to break or weaken. This could require
surgery to fix the damaged tendon or ligament. Call your healthcare
provider right away if you have trouble bending your injected
finger (towards the wrist) after the swelling goes down or you have
problems using your treated hand after your follow-up visit
- Nerve injury or other serious injury of the hand. After
finger procedures, some people developed tears in the skin
(lacerations), and local skin and soft-tissue necrosis (death of
skin cells). Some lacerations and necrosis required skin grafting,
or other surgery including amputation. Call your healthcare
provider right away if you get numbness, tingling, increased
pain, or tears in the skin (laceration) in your treated finger or
hand after your injection or after your follow-up visit
- Hypersensitivity reactions, including anaphylaxis.
Severe allergic reactions can happen in people who receive XIAFLEX
because it contains foreign proteins. Call your healthcare
provider right away if you have any of these symptoms of an
allergic reaction after an injection of XIAFLEX:
-
- hives
- swollen face
- breathing trouble
- chest pain
- low blood pressure
- dizziness or fainting
- Fainting. Fainting (passing out) or near fainting
can happen in people who receive XIAFLEX, especially following
finger procedures
If you have dizziness or feel faint after receiving XIAFLEX, lie
down until the symptoms go away.
- Increased chance of bleeding. Bleeding or bruising at
the injection site can happen in people who receive XIAFLEX. Talk
to your healthcare provider if you have a problem with your blood
clotting. XIAFLEX may not be right for you.
Before receiving XIAFLEX, tell your healthcare provider if
you have had an allergic reaction to a previous XIAFLEX
injection, or have a bleeding problem or any other medical
conditions. Tell your healthcare provider about all the medicines
you take, including prescription and non-prescription medicines,
vitamins, and herbal supplements. Using XIAFLEX with certain other
medicines can cause serious side effects. Especially tell your
healthcare provider if you take medicines to thin your blood
(anticoagulants). If you are told to stop taking a blood thinner
before your XIAFLEX injection, your healthcare provider should tell
you when to restart the blood thinner. Ask your healthcare provider
or pharmacist for a list of these medicines if you are unsure.
The most common side effects with XIAFLEX for the treatment of
Dupuytren's contracture include:
- swelling of the injection site or the hand
- bruising or bleeding at the injection site
- pain or tenderness of the injection site or the hand
- swelling of the lymph nodes (glands) in the elbow or
armpit
- itching
- breaks in the skin
- redness or warmth of the skin
- pain in the armpit
Tell your healthcare provider if you have any side effect that
bothers you or does not go away. These are not all of the possible
side effects with XIAFLEX. For more information, ask your
healthcare provider or pharmacist.
Click for full Prescribing Information, including Medication
Guide.
About Endo
Endo (OTC: ENDPQ) is a specialty
pharmaceutical company committed to helping everyone we serve live
their best life through the delivery of quality, life-enhancing
therapies. Our decades of proven success come from passionate team
members around the globe collaborating to bring treatments forward.
Together, we boldly transform insights into treatments benefiting
those who need them, when they need them. Learn more
at www.endo.com or connect with us on LinkedIn.
Cautionary Note Regarding Forward-Looking
Statements
Certain information in this press release may be
considered "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995 and any applicable
Canadian securities legislation, including, but not limited to, the
statements by Mr. Mattice and any statements relating to the video
series, patient experiences, treatment options and
XIAFLEX®, and any other statements that refer to
expected, estimated or anticipated future results or that do not
relate solely to historical facts. Statements including words or
phrases such as "believe," "expect," "anticipate," "intend,"
"estimate," "plan," "will," "may," "look forward," "intend,"
"guidance," "future," "potential" or similar expressions are
forward-looking statements. All forward-looking statements in this
communication reflect the Company's current views as of the date of
this communication about its plans, intentions, expectations,
strategies and prospects, which are based on the information
currently available to it and on assumptions it has made. Actual
results may differ materially and adversely from current
expectations based on a number of factors, including, among other
things, the following: the outcome of the Company's contingency
planning and restructuring activities; the timing, impact or
results of any pending or future litigation, investigations,
proceedings or claims, including opioid, tax and antitrust related
matters; actual or contingent liabilities; settlement discussions
or negotiations; the Company's liquidity, financial performance,
cash position and operations; the Company's strategy; risks and
uncertainties associated with Chapter 11 proceedings; the negative
impacts on the Company's businesses as a result of filing for and
operating under Chapter 11 protection; the time, terms and ability
to confirm a sale of the Company's businesses under Section 363 of
the U.S. Bankruptcy Code; the adequacy of the capital resources of
the Company's businesses and the difficulty in forecasting the
liquidity requirements of the operations of the Company's
businesses; the unpredictability of the Company's financial results
while in Chapter 11 proceedings; the Company's ability to discharge
claims in Chapter 11 proceedings; negotiations with the holders of
the Company's indebtedness and its trade creditors and other
significant creditors; risks and uncertainties with performing
under the terms of the restructuring support agreement and any
other arrangement with lenders or creditors while in Chapter 11
proceedings; the Company's ability to conduct business as usual;
the Company's ability to continue to serve customers, suppliers and
other business partners at the high level of service and
performance they have come to expect from the Company; the
Company's ability to continue to pay employees, suppliers and
vendors; the ability to control costs during Chapter 11
proceedings; adverse litigation; the risk that the Company's
Chapter 11 Cases may be converted to cases under Chapter 7 of the
Bankruptcy Code; the Company's ability to secure operating capital;
the Company's ability to take advantage of opportunities to acquire
assets with upside potential; the Company's ability to execute on
its strategic plan to pursue, evaluate and close an asset sale of
the Company's businesses pursuant to Section 363 of the U.S.
Bankruptcy Code; the impact of competition, including the loss of
exclusivity and generic competition for VASOSTRICT®; our
ability to satisfy judgments or settlements or pursue appeals
including bonding requirements; our ability to adjust to changing
market conditions; our ability to attract and retain key personnel;
our inability to maintain compliance with financial covenants and
operating obligations which would expose us to potential events of
default under our outstanding indebtedness; our ability to incur
additional debt or equity financing for working capital, capital
expenditures, business development, debt service requirements,
acquisitions or general corporate or other purposes; our ability to
refinance our indebtedness; a significant reduction in our
short-term or long-term revenues which could cause us to be unable
to fund our operations and liquidity needs or repay indebtedness;
supply chain interruptions or difficulties; changes in competitive
or market conditions; changes in legislation or regulatory
developments; our ability to obtain and maintain adequate
protection for our intellectual property rights; the timing and
uncertainty of the results of both the research and development and
regulatory processes, including regulatory decisions, product
recalls, withdrawals and other unusual items; domestic and foreign
health care and cost containment reforms, including government
pricing, tax and reimbursement policies; technological advances and
patents obtained by competitors; the performance, including the
approval, introduction, and consumer and physician acceptance of
new products and the continuing acceptance of currently marketed
products; our ability to integrate any newly acquired products into
our portfolio and achieve any financial or commercial expectations;
the impact that known and unknown side effects may have on market
perception and consumer preference for our products; the
effectiveness of advertising and other promotional campaigns; the
timely and successful implementation of any strategic initiatives;
unfavorable publicity regarding the misuse of opioids; the
uncertainty associated with the identification of and successful
consummation and execution of external corporate development
initiatives and strategic partnering transactions; our ability to
advance our strategic priorities, develop our product pipeline and
continue to develop the market for QWO® and other
products; and our ability to obtain and successfully manufacture,
maintain and distribute a sufficient supply of products to meet
market demand in a timely manner. In addition, U.S. and
international economic conditions, including consumer confidence
and debt levels, inflation, taxation, changes in interest and
currency exchange rates, international relations, capital and
credit availability, the status of financial markets and
institutions, the impact of and response to the ongoing COVID-19
pandemic and the impact of continued economic volatility, can
materially affect our results. Therefore, the reader is cautioned
not to rely on these forward-looking statements. Endo expressly
disclaims any intent or obligation to update these forward-looking
statements, except as required to do so by law.
Additional information concerning risk factors, including those
referenced above, can be found in press releases issued by Endo, as
well as Endo's public periodic filings with the U.S. Securities and
Exchange Commission and with securities regulators in Canada, including the discussion under the
heading "Risk Factors" in Endo's most recent Annual Report on Form
10-K and any subsequent Quarterly Reports on Form 10-Q or other
filings with the U.S. Securities and Exchange Commission. Copies of
Endo's press releases and additional information about Endo are
available at www.endo.com or you can contact the Endo Investor
Relations Department at relations.investor@endo.com.
Logo -
https://mma.prnewswire.com/media/530208/Endo_International_plc_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/endo-launches-unscripted-video-series-with-real-dupuytrens-contracture-patients-301640965.html